Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
in vivo CAR-T
Biotech
Create Medicines fashions $122M raise for in vivo CAR-T dreams
Create’s approach is to use mRNA to turn cells in patients’ bodies against their disease, be it cancer cells or overactive immune cells.
Darren Incorvaia
May 14, 2026 9:42am
Novartis CEO ‘continuing to evaluate’ in vivo CAR-Ts
Apr 28, 2026 3:21am
After Lilly-Kelonia deal, are any in vivo biotechs left to buy?
Apr 24, 2026 9:30am
Lilly bags another in vivo CAR-T biotech via $7B Kelonia deal
Apr 20, 2026 10:15am
AstraZeneca in vivo data shows potential, despite patient death
Mar 27, 2026 11:00am
Allogeneic CAR-T biotechs fight to escape 'nuclear winter'
Feb 11, 2026 11:00am
